Relationship between psoriasis severity, clinical symptoms, quality of life and work productivity among patients in the USA

Clinical and Experimental Dermatology

Volumn 41, Issue 5, 2016, Pages 514-521

  Korman, N J ^a   Zhao, Y ^b   Pike, J ^c   Roberts, J ^c  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c ADELPHI REAL WORLD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL FEATURE; COMORBIDITY; DEMOGRAPHY; DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY; EUROQOL 5 DIMENSION HEALTH QUESTIONNAIRE; FEMALE; HEALTH SURVEY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBESITY; OBSERVATIONAL STUDY; PAIN; PRIORITY JOURNAL; PRODUCTIVITY; PRURITUS; PSORIASIS; QUALITY OF LIFE; QUESTIONNAIRE; RETROSPECTIVE STUDY; UNITED STATES; WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE;

EID: 84975230516     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/ced.12841     Document Type: Article

References (24)

1. Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol 2014; 70: 512–16.
2. Krueger GG, Feldman SR, Camisa C et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000; 43: 281–5.
3. Armstrong AW, Schupp C, Wu J, Bebo B. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation Survey Data 2003–2011. PLoS ONE 2012; 7: e52935.
4. Perrott SB, Murray AH, Lowe J, Mathieson CM. The psychosocial impact of psoriasis: physical severity, quality of life, and stigmatization. Physiol Behav 2000; 70: 567–71.
5. Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R. Quality of life in patients with psoriasis. Health Qual Life Outcomes 2006; 4: 35.
6. Choi J, Koo JY. Quality of life issues in psoriasis. J Am Acad Dermatol 2003; 49: 57–61.
7. Korman N. Comorbid disease in psoriasis. Available at: http://www.uptodate.com/contents/comorbid-disease-in-psoriasis (accessed 2 May 2014).
8. De Korte J, Sprangers MA, Mombers FM, Bos JD. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc 2004; 9: 140–7.
9. Heydendael VM, de Borgie CA, Spuls PI et al. The burden of psoriasis is not determined by disease severity only. J Investig Dermatol Symp Proc 2004; 9: 131–5.
10. Gelfand JM, Feldman SR, Stern RS et al. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol 2004; 51: 704–8.
11. Weiss SC, Kimball AB, Liewehr DJ et al. Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol 2002; 47: 512–18.
12. Daudén E, Conejo J, García-Calvo C. Physician and patient perception of disease severity, quality of life, and treatment satisfaction in psoriasis: an observational study in Spain. Actas Dermosifiliogr 2011; 102: 270–6.
13. Roblin D, Wickramasinghe R, Yosipovitch G. Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity. J Am Acad Dermatol 2014; 70: 390–1.
14. Anderson P, Benford M, Harris N et al. Real-world physician and patient behaviour across countries: Disease-Specific Programmes – a means to understand. Curr Med Res Opin 2008; 24: 3063–72.
15. EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199–208.
16. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210–16.
17. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993; 4: 353–65.
18. Krueger G, Koo J, Lebwohl M et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280–4.
19. Verhoeven EWM, Kraaimaat FW, van de Kerkhof PCM et al. Prevalence of physical symptoms of itch, pain and fatigue in patients with skin diseases in general practice. Br J Dermatol 2007; 156: 1346–9.
20. Ragnarson Tennvall G, Hjortsberg C, Bjarnason A et al. Treatment patterns, treatment satisfaction, severity of disease problems, and quality of life in patients with psoriasis in three Nordic countries. Acta Derm Venereol 2013; 93: 442–5.
21. National Institutes of Health. Overweight and obesity statistics. Available at: http://wwwniddknihgov/health-information/health-statistics/Pages/overweight-obesity-statisticsaspx (accessed 12 August 2015).
22. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol 2013; 68: 654–62.
23. Cohen A, Dreiher J, Shapiro Y et al. Psoriasis and diabetes: a population-based cross-sectional study. J Eur Acad Dermatol Venereol 2008; 22: 585–9.
24. Mckenna KE, Stern RS. The outcomes movement and new measures of the severity of psoriasis. J Am Acad Dermatol 1996; 34: 534–8.